Reply to "Apparent Commericial Bias in Supplement"

View This PDF

NB: This article is only available as a PDF.

Letter to the Editor

Sir: As chair of the supplement “Translating the Psychopharmacology of Antipsychotics to Individualized Treatment for Severe Mental Illness: A Roadmap,” I would like to personally respond to the concerns put forth in Dr. Carlat’s letter regarding the scientific integrity of this publication.

His letter contends that the selection of items in the survey was “influenced by the fact that Bristol-Myers Squibb sponsored the production of the article.” He disputes our statement of our criteria for item selection. Dr. Carlat’s contention is that we chose specific questions that were likely to show the relative advantages of aripiprazole compared with other medication options.

J Clin Psychiatry 2008;69(6):1020